Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06615375Phase 2Active Not Recruiting

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Role: lead

NCT06719219Phase 1Completed

A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

Role: lead

NCT06190509Phase 1Active Not Recruiting

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Role: lead

NCT06523231Phase 2Completed

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

Role: lead

NCT04056117Phase 1Completed

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Role: lead

NCT04959344Phase 1Completed

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

Role: lead

NCT02646371Phase 2Completed

Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a

Role: lead

NCT03303976Phase 1Completed

Phase I to Test a New Pneumococcal Vaccine

Role: lead

NCT02388009Phase 1Completed

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

Role: lead

All 9 trials loaded